AI Article Synopsis
- Chiari network is a result of incomplete resorption of the right valve of the sinus venosus, often appearing as a membranous or reticular structure in the inferior vena cava and coronary sinus.
- A study of 80 cadaveric hearts found Chiari network incidence at 3.75% and remnants of the left venous valve at 7.5%, with various morphological presentations observed.
- Understanding these embryological remnants is crucial due to their potential to cause diagnostic confusion and complications during medical procedures.
Article Abstract
Chiari network occurs due to incomplete resorption of right valve of sinus venosus. It is often noticed as fenestrated membranous structure or reticular network like structure in the valve of inferior vena cava and coronary sinus. The remnant of left venous valve is observed as trabeculae over the fossa ovalis. The incidence of Chiari network and the remnant of left venous valve were studied in 80 cadaveric hearts utilized for teaching the undergraduates. The right atrium was opened anterior to sulcus terminalis and the interior was examined for the presence of these embryological remnants. The incidence of Chiari network and left venous valve in the present study is 3.75% and 7.5%, respectively. Chiari network was observed as a fenestrated membranous structure in 2 specimens and a reticular network in 1 specimen, with variable extension to coronary sinus opening and right atrial wall. The remnant of left venous valve was observed as multiple fine strands in 3 specimens and trabecular structure in 3 specimens. These structures may create diagnostic confusion, difficulty in interventional procedures, and complications like thromboembolic events. Hence, the knowledge about the incidence, morphology, and clinical manifestations of these rare embryological remnants is mandatory.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4579302 | PMC |
| http://dx.doi.org/10.1155/2015/247680 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Manifestations.
Alzheimers Dement
December 2024
Neurologia, Azienda Ospedaliero Universitaria di Modena, Modena, Italy.
Background: Recent evidence suggests that unawareness in Alzheimer's disease (AD) continuum can be explained by a failure of the connections between brain regions involved in accessing and monitoring self and other information. It has been demonstrated that AD patients with anosognosia have reduced network connectivity in the default mode network (DMN); in addition, stronger connectivity of bilateral anterior cingulate cortex (ACC) was showed to be associated with anosognosia in prodromal AD suggesting a possible role of this region in mechanisms of "adaptation" to anosognosia early in the disease. Therefore, we hypothesized that anosognosia in AD could be associated with an imbalance between the activity of the DMN and the salience network (SN) detectable using resting state functional magnetic resonance imaging (fMRI).
View Article and Find Full Text PDFGiant thrombus formation in Chiari network after surgical closure of atrial septal defect: a case report.
Eur Heart J Case Rep
January 2025
Cardiology Department, University Virgen de las Nieves Hospital, Avenida de las Fuerzas Armadas 2, Granada 18014, Spain.
Aspiration thrombectomy of the hepatic veins in Budd Chiari Syndrome.
Acta Gastroenterol Belg
January 2025
Department of Radiology, Antwerp University Hospital, Antwerp, Belgium.
Budd-Chiari syndrome (BCS) is a rare, potentially lifethreatening condition characterised by obstruction of the hepatic venous outflow tract due to thrombosis. Treatment typically involves lifelong anticoagulation and relieving the obstruction. This case report introduces hepatic venous thromboaspiration as an additional endovascular technique to achieve recanalisation.
View Article and Find Full Text PDFPostmarketing Safety Surveillance of Topiramate: A Signal Detection and Analysis Study Based on the FDA Adverse Event Reporting System Database.
J Evid Based Med
December 2024
School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, China.
Objective: This study aims to investigate the occurrence of adverse events associated with topiramate by analyzing data from the FDA Adverse Event Reporting System. The goal is to provide a basis for the safe clinical use of topiramate.
Methods: Adverse event data from the FDA Adverse Event Reporting System, from its inception through the first quarter of 2024, were extracted.
The Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design: A Trial Protocol.
JAMA Netw Open
December 2024
Renal and Metabolic Division, The George Institute for Global Health, University of New South Wales, Sydney, Australia.
Importance: Chronic kidney disease (CKD) is a global health priority affecting almost 1 billion people. New therapeutic options and clinical trial innovations such as adaptive platform trials provide an opportunity to efficiently test combination therapies.
Objective: To describe the design and baseline results of the Global Kidney Patient Trials Network (GKPTN) and the design and structure of the global adaptive platform clinical trial Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect (CAPTIVATE) to find new therapeutic options and treatments for people with kidney disease.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!